ATNX - Athenex: The CRL Is Devastating March, 09 2021 06:44 AM Athenex Inc. Athenex received a CRL from the FDA for its lead asset Oraxol. The CRL will require them to conduct a new phase 3 trial in the US. This is a major setback for ATNX. For further details see: Athenex: The CRL Is Devastating